On March 8, Hunan Fangsheng Pharmaceutical Co.Ltd(603998) announced that it had received the notice of approval of supplementary application for cefixime tablets issued by the State Drug Administration, confirming that the drug had passed the consistency evaluation of quality and efficacy of generic drugs.
According to the data of Intranet, the sales of cefixime oral preparations in China in 2019 and 2020 were about 3.612 billion yuan and 2.732 billion yuan respectively. As of the date of this announcement, cefixime tablets from three manufacturers (Zhejiang Jutai Pharmaceutical Co., Ltd., Shandong Haishan Pharmaceutical Co., Ltd., Hunan Fangsheng Pharmaceutical Co.Ltd(603998) ) have passed the approval of the quality and efficacy consistency evaluation of generic drugs by the State Drug Administration.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) said that the conformity evaluation of the quality and efficacy of cefixime tablets through generic drugs, on the one hand, has promoted the import and original research substitution of cefixime oral preparations in China, on the other hand, it is also expected to promote the evaluated enterprises to benefit from the structural opportunities of the changing situation of the industry and increase the market share.
Recently, Hunan Fangsheng Pharmaceutical Co.Ltd(603998) has made frequent moves. On the one hand, Zhou Xiaoli, a “marketing veteran” of Hunan Fangsheng Pharmaceutical Co.Ltd(603998) was elected as the chairman of the board. On the other hand, the plan for non-public offering of shares in 2022 and the incentive plan for restricted shares in 2022 were launched simultaneously We are committed to building a healthy Chinese medicine group with innovation as its core.
According to the fixed increase plan, Hunan Fangsheng Pharmaceutical Co.Ltd(603998) plans to raise no more than 270 million yuan at the issue price of 4.74 yuan / share, and the Xinyuan property investment controlled by Hunan Fangsheng Pharmaceutical Co.Ltd(603998) actual controller Zhang Qinghua will subscribe for the fixed increase, and its proportion of control will be increased from 39.69% to 46.76%.
It is disclosed that since the listing, Zhang Qinghua has never reduced his direct or indirect shares of listed companies. This time, Zhang Qinghua subscribed for a fixed increase based on his confidence in the future development of listed companies, and will lock it for 36 months.
Since 2021, Hunan Fangsheng Pharmaceutical Co.Ltd(603998) accelerated the sorting of business segments in accordance with the principle of “retreat and progress, focus on the main business”. On the one hand, Hunan Fangsheng Pharmaceutical Co.Ltd(603998) will transfer the chain medical companies and cro companies in the body one after another; On the other hand, in order to shorten the management radius and improve the use efficiency of production capacity, Hunan Fangsheng Pharmaceutical Co.Ltd(603998) made strategic adjustments to pharmaceutical bases away from the headquarters, actively improved the use efficiency of headquarters assets, gave play to intensive advantages and continuously improved profitability by means of entrusted production, transfer of main approvals and disposal of solidified assets.
